Remarks

Claims 34-40 and 47-49 are pending in the subject application. By this Amendment, Applicants have amended claim 37. Support for the amendments can be found throughout the subject specification and in the claims as originally filed (see, for example, page 48, lines 22-24, of the specification). Entry and consideration of the amendments presented herein is respectfully requested. Accordingly, claims 34-40 and 47-49 are currently before the Examiner. Favorable consideration of the pending claims is respectfully requested.

As an initial matter, Applicants gratefully acknowledge the Examiner's withdrawal of the objections to the specification and the rejection under 35 U.S.C. §102(b) over Pan et al.

Claims 37, 40, and 49 are rejected under 35 U.S.C. § 112, second paragraph, as indefinite. The Office Action indicates that the recitation of the limitation "at least six consecutive amino acids ... spans positions 92 and 98" causes the claim to be vague and indefinite. Applicants respectfully submit that claim 37 is not vague or indefinite. Applicants respectfully submit that the plain reading of the claim indicates that the claimed fragment is at least six consecutive amino acids of SEQ ID NO: 58 and that the fragment contains at least six of the amino acids located at positions 92 through 98 of SEQ ID NO: 58. However, in the interest of expediting prosecution in this matter, Applicants have amended claim 37 in a fashion that renders this issue moot. Accordingly, reconsideration and withdrawal of the rejection under 35 U.S.C. § 112, second paragraph, is respectfully requested.

Claims 37, 40, and 49 are rejected under 35 U.S.C. § 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventors, at the time the application was filed, had possession of the claimed invention. Applicants respectfully assert that there is adequate written description in the subject specification to convey to the ordinarily skilled artisan that they had possession of the claimed invention; however, in the interest of expediting prosecution in this matter, Applicants have amended claim 37 to delete the limitation of "fragment spans positions 92 and 98 of SEQ ID NO: 58" thereby rendering this rejection moot. Accordingly, reconsideration and withdrawal of the rejection under 35 U.S.C. § 112, first paragraph, is respectfully requested.

Claims 34-49 are rejected under 35 U.S.C. § 101 and 35 U.S.C. § 112, first paragraph, on the ground that the claimed invention is not supported by a well-established utility. The Office Action

argues that the utilities indicated within the specification are non-specific or particular to the claimed sequence. For example, the Office Action argues that the use of the claimed sequence as a substrate for various proteases, in animal models, for the diagnosis of diseases or disorders associated with abnormalities of the metabolism of collage or the monitoring of collagen degradation are non-specific uses that are applicable to a large family of structurally related collagen related proteins and which are not specific to the polypeptide being claimed. Applicants, again, respectfully traverse.

The examiner bears the initial burden of showing that a claimed invention lacks patentable utility. See In re Brana, 51 F.3d 1560, 1566, 34 USPQ2d 1436, 1441 (Fed. Cir. 1995) ("Only after the PTO provides evidence showing that one of ordinary skill in the art would reasonably doubt the asserted utility does the burden shift to the applicant to provide rebuttal evidence sufficient to convince such a person of the invention's asserted utility."). It is respectfully submitted that the Office Actions issued in this matter have failed to provide any evidence showing that the asserted utility would be doubted by those of ordinary skill in the art.

In the initial Office Action, the Patent Office argued that the asserted utilities of the claimed polypeptide was not credible, specific, or substantial on the grounds that the paper first reporting the isolation of the human alpha 1 type XVI collagen (also known as COL16A1) authored by Pan *et al.* in 1992 states that "structural similarities between the $\alpha 1$ type XVI collagen and the FACIT group raise the intriguing possibility that the $\alpha 1$ (XVI) collagen may serve similar functions". This position has been maintained in the subsequent Office Action.

Applicants respectfully submit that the Office Actions fail to take into account further information developed with regards to all type XVI collagen after the publication of Pan et al. For example, a number of splice variants of the human alpha 1 type XVI collagen are known (see attached EMBL-EBI Altsplice printout indicating eleven (11) known splice variants). Additionally, review texts documenting the state of the art for what the authors termed "unconventional collagens" (including human alpha 1 type XVI collagen) have been written (see *Unconventional Collagens Types VI, VIII, VIII, IX, X, XIV, XVI and XIX*, S. Ricard-Blum et al., Oxford Press, 2000, attached hereto), and, as indicated in the attached ENTREZ PROTEIN and ENTREZ GENE printouts, members of this collagen family are found in association with fibril-forming collagens such as type I and II and serve to maintain the integrity of the extracellular matrix. Finally, high levels of type XVI

collagen have been found in fibroblasts and keratinocytes, and in smooth muscle and amnion. Thus, it is respectfully submitted that the Patent Office has failed to show that one skilled in the art would reasonably doubt the utilities asserted with respect to the claimed polypeptide, particularly in view of the knowledge regarding such polypeptides that was gathered subsequent to the publication of Pan *et al*.

As set forth in the specification, the instantly claimed invention has utility for: the diagnosis of diseases or disorders associated with abnormalities of the metabolism of collagen; use in assays (in vitro) as a substrate of proteases; the treatment of diseases and conditions associated with collagen matrix destruction, including for wound treatment; for preparing cosmetic compositions such as skin creams with anti-wrinkle activity; or use as an injectable biomaterial. Applicants respectfully submit that the fact that the claimed polypeptide has certain uses that overlap with other structurally related proteins (collagens) is not controlling as to whether the claimed polypeptide has a utility that is specific, credible, substantial or well-established. For example, the subject specification indicates that the claimed polypeptide can be used as an injectable biomaterial or in cosmetic compositions. As the Patent Office may be aware, injectable collagen is used in the fields of plastic surgery for a variety of purposes, including for lip augmentation and to rectify facial defects, frown lines and acne scars (see paragraph 983 of the published application). Thus, it is respectfully submitted that one skilled in the art would recognize that the instantly claimed invention would have a specific, credible, substantial and well-established utility for use in the field of plastic surgery as an injectable composition. Further, it is respectfully submitted that one skilled in the pertinent arts would be able to use the subject invention in view of the teachings of the application and/or the skill/knowledge of the artisan of the relevant field of endeavor. Accordingly, reconsideration and withdrawal of the rejections is respectfully requested.

Claims 37, 40, and 49 are rejected under 35 U.S.C. § 102(b) as anticipated by Olsen *et al.* (1999). The Office Action states that the Olsen *et al.* reference discloses a collagen polypeptide fragment comprising at least six consecutive amino acids which spans positions 92 and 98 of SEQ ID NO: 58. Applicants respectfully submit that the cited reference does not anticipate the presently claimed invention. However, by this Amendment, Applicants have amended claim 37 to delete the limitation of "fragment spans positions 92 and 98 of SEQ ID NO: 58" thereby rendering this

7

rejection moot. Accordingly, reconsideration and withdrawal of the rejection under 35 U.S.C. § 102(b) is respectfully requested.

It should be understood that the amendments presented herein have been made <u>solely</u> to expedite prosecution of the subject application to completion and should not be construed as an indication of Applicants' agreement with or acquiescence in the Examiner's position. Applicants expressly reserve the right to pursue the invention(s) disclosed in the subject application, including any subject matter canceled or not pursued during prosecution of the subject application, in a related application.

In view of the foregoing remarks and amendments to the claims, Applicants believe that the currently pending claims are in condition for allowance, and such action is respectfully requested.

The Commissioner is hereby authorized to charge any fees under 37 CFR §§1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Applicants invite the Examiner to call the undersigned if clarification is needed on any of this response, or if the Examiner believes a telephonic interview would expedite the prosecution of the subject application to completion.

Respectfully submitted,

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100 Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl

Attachments: EMBL-EBI Altsplice printout

Unconventional Collagens Types VI, VII, VIII, IX, X, XIV, XVI and XIX, S. Ricard-

Blum et al., Oxford Press, 2000, abstract only ENTREZ PROTEIN and ENTREZ GENE printouts

GENE INFORMATION :

GENE ONTOLOGY:

MOLECULAR FUNCTION:

EBI Home About EBI Groups Services Toolbox

Dalabases

Downloads Submissions

Wrapper Query Page

AltSplice Entry Display ASD

Help

Altsplice-Human: Entry ENSG0000084636

Gene symbols :	COL16A1 , 447AA , FP1572
Protein description :	Collagen alpha 1(XVI) chain precursor. [Source:Uniprot/SWISSPROT;Acc:Q07092]
Gene sequence :	View the gene sequence
CHROMOSOME INFORMATION:	
Chromosome:	1
Contig start-end :	31783941 - 31841742
Strand :	Minus
CROSS REFERENCES:	
EnsEMBL gene :	ENSG00000084636
EnsEMBL Transcript/Peptide :	ENST00000271069 (ENSP00000271069.5)
Uniprot/SwissProt :	Q07092
EMBL:	M92642 , S57132
REFSEQ:	NP_001847 , NM_001856
GO:	GO:0007155 , GO:0007565 , GO:0006817 , GO:0005201 , GO:0005737 , GO:0005578 , GO:0005597
PROTEIN ID :	AAA58427 , AAB25797
INTERPRO:	IPR003979 , IPR000694 , IPR002965 , IPR008160

constituent: (GO:0005201)

(GO:0005578)

structural molecule activity; extracellular matrix structural


extracellular region; extracellular matrix (sensu Metazoa):

CELLULAR COMPONENT:	extracellular region ; extracellular matrix (sensu Metazoa) ; collagen : (GO:0005597) cell ; intracellular ; cytoplasm : (GO:0005737)
BIOLOGICAL PROCESS :	physiological process; cellular physiological process; transport: (G0:0006817) physiological process; organismal physiological process; reproductive physiological process: (G0:0007565) cellular process; cell communication; cell adhesion: (G0:0007155)

EVIDENCES: Human-Mouse Conservation: o Intron/Exon level ENSMUSG00000040690

Clik on this link displays a page giving reference transcript structure and

Confirmed introns/exons: confirmed introns/exons



Legend: A dashed line between features indicates a gap on the pattern where an intron couldn't be fully confirmed.

numl: number of libraries that confirm this pattern.

SP: indicates the index of the splice pattern. Putting the mouse pointer over a "SP" text ("mouse-over") brings up a pop-up window with expression state information, links to splice pattern table (with the appropriate splice pattern as high-lighted) along with expression state information and pattern sequence.

Putting the mouse pointer over an exon/intron feature brings up a pop-up window with link to sequence page of the feature.

Splice patterns on Ensembl browser Show Splice Patterns along the contig via Ensembl DAS source

How do I set the DAS server up for the first time ?

Splice Pattern Table					
PATTERN SEQUENCE	PEPTIDE SEQUENCE	STRUCTURE	CONFIRMING EST/mRNA's	CLONE LIBRARIES	IDENTIFIED SNP's
1		~3704837238, 3819438247, 3883138884, 3942139474, 4096841012, 41114~41168, ~4143141466, 4181541877, 4439144462, 4466244715, 45345~45384	4	4	19
2		~4535245389, 4559145635, 4593045983, 4641146464, 4808548135, 4847248561, 4998150016, 5060550649, 51547~51736	3	3	11
3		~4592845983, 4641146464, 4808548135, 4847248561, 4998150016, 5060550649, 5154751735, 5219152257, 53006~53145	2	1	15
4		~4998150016, 5060550649, 5154751735, 5219152257, 5300653182, 5337353450, 54196~54237	16	14	12
5	4856.9125 (211 aa)	~31843212, 48224928, 69347008, 7119~7236, ~84458566, 8877~9143	7	5	11
6		~84658566, 88779143, 97499829, 996110086, 10908~10963	1	1	4
7		~4066441012, 41114~41168, ~4143141466, 4181541877, 44391~44462	1	1	4
8		~2076820805, 2091420958, 2127921410, 22193~22229	3	2	3

9	~29893212, 69347008, 7119~7236	1	1	7
10	~3640636493, 3819438247, 38831~38885	1	1	7
11	~5120151735, 5219152257, 53006~53183	2	2	5

o View all the splice pattern sequences

Splice Events:

Cassette Exon Event				
CASSETTE EXON(s)	EVENT TYPE	AEDB ASSOCIATION	CONSERVATION	
48224928	SCE			



Please contact <u>EBI Support</u> with any problems or suggestions regarding this site.

<u>EBI Support</u> with any problems or suggestions regarding this site.


<u>I Support</u> with any problems or suggestions regarding this site.

Books









Journals

All Databa	ses PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC
Search Put	oMed	for		•		Go	Clear
	Limits	S Preview/Index	· History	✓ Clipboa	rd Details	ŝ	
About Entrez	Display	Abstract	Sh	ow 20 🔄	Sort by	Send to	Œ
ADOUL EHRIEZ	All: 1	Review: 0					

Related Articles, Links

Entrez PubMed Overview Help | FAQ Tutorial

New/Noteworthy

E-Utilities

Text Version

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI

Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

1: J Cell Sci. 2000 Dec;113 (Pt 23):4141-2.

Unconventional collagens

ics biologists org

Knight DP.

Unconventional Collagens Types VI, VII, VIII, IX, X, XIV, XVI and XIX by S. Ricard-Blum, B. Dublet and M. van der Rest Oxford University Press (2000) pp.155. ISBN 0-19-850545-0 35.00 This thoroughly researched monograph in Oxford University Press's 'Protein Profile Series' reviews substantially all the significant literature on this interesting and highly important group of proteins. The authors use the term 'Unconventional Collagens' for the collagens of higher vertebrate connective tissues which do not, of themselves, form classical fibrils with a 68 nm banding pattern. The authors chose to omit type IV collagen as this, they claim, would have almost doubled the size of the volume. The monograph represents a very considerable achievement in three respects. Firstly it comprehensively reviews the literature on the sequence, structure, expression, posttranslational modification, genetics, physiological function and pathology of each separate unconventional collagen. The thoroughness of this review is indicated by the fact that the bibliography contains no fewer than 1196 references. Secondly, the monograph identifies the modular domain structure for each collagen, clearly demonstrating that these proteins are block co-polymers mainly derived in evolution from a small number of ancestral genes. Thirdly, it starts to identify the way in which the different modules of these sticky molecules interact with each other and with other connective tissue components. This is an important start if we are to understand their vital role in the self-assembly processes which occur in embryology, tissue repair and the major degenerative and collagen gene diseases The clearly written and well set out text is supported by excellent micrographs of rotary shadowed molecules and molecular aggregates and a wealth of diagrams and tables. The book has, in my view, three minor shortcomings: a short summary chapter on type IV would enable the non-specialist reader to relate this collagen to the other non-conventional collagens. Concise summaries at the ends of each chapter would orient newcomers to the field. More significantly, apart from the brief introduction, the book lacks an overall synthesis which pulls together the findings of the separate chapters. These slight limitations aside, this book is essential reading for those engaged in connective tissue research and will do much to stimulate further activity in this area. It will also be of considerable interest to tissue engineers, pathologists and embryologists.

PMID: 0011069758 [PubMed - as supplied by publisher]

Display Abstract	Show 20	Sort by	Send to	

My NCBI [Sign In] [Register]

PubMed

Nucleotide

Limits

Protein

Genome

Structure

PMC

Taxonomy

Go

OMIM Books

Search Protein

for

Preview/Index

History

Clipboard

Clear Details

Display GenPept

Send to Show 5

Range: from begin

to end

Features: SNP CDD MGC HPRD STS VtRNA

Refresh

☐ 1: NP 001847. Reports alpha 1 type XVI ...[gi:18641352]

BLink, Conserved Domains, Links

LOCUS NP 001847

1603 aa

PRI 16-OCT-2005 linear

DEFINITION alpha 1 type XVI collagen precursor [Homo sapiens].

NP 001847 ACCESSION

NP 001847.2 GI:18641352 VERSION **DBSOURCE** REFSEQ: accession NM 001856.2

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini;

Hominidae; Homo.

REFERENCE (residues 1 to 1603)

AUTHORS Kassner, A., Tiedemann, K., Notbohm, H., Ludwig, T., Morgelin, M.,

Reinhardt, D.P., Chu, M.L., Bruckner, P. and Grassel, S.

TITLE Molecular structure and interaction of recombinant human type XVI

collagen

J. Mol. Biol. 339 (4), 835-853 (2004) **JOURNAL**

PUBMED 15165854

GeneRIF: interacts with fibrillin-1 and with fibronectin indicating REMARK

> multiple molecular interactions in which this ubiquitously expressed and versatile fibril-associated collagens with interrupted triple helices-collagen can participate

REFERENCE (residues 1 to 1603)

AUTHORS Kassner, A., Hansen, U., Miosge, N., Reinhardt, D.P., Aigner, T.,

Bruckner-Tuderman, L., Bruckner, P. and Grassel, S.

TITLE Discrete integration of collagen XVI into tissue-specific collagen

fibrils or beaded microfibrils

JOURNAL Matrix Biol. 22 (2), 131-143 (2003)

PUBMED 12782140

REMARK GeneRIF: Not in banded collagen fibrils in dermis, but is component

of specialized fibrillin-1-containing microfibrils. In cartilage matrix not in aggregates with fibrillin-1. Resides in thin, weakly banded collagen fibrils also containing collagens II and XI.

(residues 1 to 1603) REFERENCE

AUTHORS Grassel, S., Timpl, R., Tan, E.M. and Chu, M.L.

TITLE Biosynthesis and processing of type XVI collagen in human

fibroblasts and smooth muscle cells

JOURNAL Eur. J. Biochem. 242 (3), 576-584 (1996)

PUBMED 9022684

REFERENCE (residues 1 to 1603)

AUTHORS Sires, U.I., Dublet, B., Aubert-Foucher, E., van der Rest, M. and

Welgus, H.G.

Degradation of the COL1 domain of type XIV collagen by 92-kDa TITLE

gelatinase

JOURNAL J. Biol. Chem. 270 (3), 1062-1067 (1995)

PUBMED 7836360

REFERENCE (residues 1 to 1603)

AUTHORS Yamaguchi, N., Kimura, S., McBride, O.W., Hori, H., Yamada, Y.,

Kanamori, T., Yamakoshi, H. and Nagai, Y.

TITLE Molecular cloning and partial characterization of a novel collagen


```
chain, alpha 1(XVI), consisting of repetitive collagenous domains
            and cysteine-containing non-collagenous segments
  JOURNAL
            J. Biochem. 112 (6), 856-863 (1992)
   PUBMED
            1284248
REFERENCE
            6 (residues 1 to 1603)
            Pan, T.C., Zhang, R.Z., Mattei, M.G., Timpl, R. and Chu, M.L.
 AUTHORS
            Cloning and chromosomal location of human alpha 1(XVI) collagen
  TITLE
  JOURNAL
            Proc. Natl. Acad. Sci. U.S.A. 89 (14), 6565-6569 (1992)
   PUBMED
            1631157
COMMENT
            REVIEWED REFSEQ: This record has been curated by NCBI staff. The
            reference sequence was derived from M92642.1 and R54778.1.
            On Feb 8, 2002 this sequence version replaced gi: 11386159.
            Summary: This gene encodes the alpha chain of type XVI collagen, a
            member of the FACIT collagen family (fibril-associated collagens
            with interrupted helices). Members of this collagen family are
            found in association with fibril-forming collagens such as type I
            and II, and serve to maintain the integrity of the extracellular
            matrix. High levels of type XVI collagen have been found in
            fibroblasts and keratinocytes, and in smooth muscle and amnion.
FEATURES
                     Location/Qualifiers
                     1..1603
     source
                     /organism="Homo sapiens"
                     /db xref="taxon:9606"
                     /chromosome="1"
                     /map="1p35-p34"
     Protein
                     1..1603
                     /product="alpha 1 type XVI collagen precursor"
                     /note="collagen XVI, alpha-1 polypeptide; alpha 1 type XVI
                     collagen"
                     1..21
     sig peptide
                     /calculated mol wt=2386
     mat peptide
                     22..1603
                     /product="alpha 1 type XVI collagen"
                     /calculated mol wt=155312
     CDS
                     1..1603
                     /gene="COL16A1"
                     /coded by="NM 001856.2:247..5058"
                     /note="go component: cytoplasm [goid 0005737] [evidence
                     IEA];
                     go component: collagen type XVI [goid 0005597] [evidence
                     TAS] [pmid 1284248];
                     go component: extracellular matrix (sensu Metazoa) [goid
                     0005578] [evidence IEA];
                     go function: structural molecule activity [goid 0005198]
                     [evidence IEA];
                     go process: cell adhesion [goid 0007155] [evidence IEA];
                     go process: pregnancy [goid 0007565] [evidence TAS] [pmid
                     1284248];
                     go process: phosphate transport [goid 0006817] [evidence
                     IEA]"
                     /db xref="GeneID:1307"
                     /db xref="HGNC:2193"
                     /db xref="HPRD:00381"
                     /db_xref="MIM:120326"
ORIGIN
        1 mwvswapglw llglwatfgh gantgaqcpp sqqeglkleh ssslpanvtg fnlihrlslm
       61 kksaikkirn pkgplilrlg aapvtgptrr vfprglpeef alvltlllkk hthgktwylf
      121 qvtdangypq islevnsqer slelraqgqd gdfvscifpv pqlfdlrwhk lmlsvagrva
      181 svhvdcssas sqplgprrpm rpvghvflgl daeqgkpvsf dlqqvhiycd pelvleegcc
      241 eilpagcppe tskarrdtqs nelieinpqs egkvytrcfc leepqnsevd aqltgrisqk
      301 aergakvhqe taadecppcv hgardsnvtl apsgpkggkg erglpgppgs kgekgargnd
      361 cvrispdapl qcaegpkgek gesgalgpsg lpgstgekgq kgekgdggik gvpgkpgrdg
      421 pgeicvigpk gqkgdpgfvg peglagepgp pqlpgppqig lpgtpgdpgg ppgpkgdkgs
      481 sgipgkegpg gkpgkpgvkg ekgdpcevcp tlpegfqnfv glpgkpgpkg epgdpvrarg
```

```
541 dpgiqgikge kgepclscss vvgaqhlvss tgasgdvgsp gfglpglpgr agvpglkgek
 601 gnfgeagpag spgppgpvgp agikgakgep cepcpalsnl qdgdvrvval pgpsgekgep
 661 gppgfglpgk qgkagerglk gqkgdagnpg dpgtpgttgr pglsgepgvq gpagpkgekg
 721 dgctacpslq gtvtdmagrp gqpgpkgeqg pegvgrpgkp gqpglpgvqg ppglkgvqge
 781 pgppgrgvqg pqgepgapgl pgiqglpgpr gppgptgekg aqgspgvkga tgpvgppgas
 841 vsgppgrdgq qgqtglrgtp gekgprgekg epgecscpsq gdlifsgmpg apglwmgssw
 901 qpgpqgppgi pgppgppgvp glqgvpgnng lpgqpgltae lgslpieqhl lksicgdcvq
 961 gqrahpgylv ekgekgdqgi pgvpgldnca qcflslerpr aeeargdnse gdpgcvgspg
1021 lpgppglpgq rgeegppgmr gspgppgpig ppgfpgavgs pglpglqger gltgltgdkg
1081 epgppgqpgy pgatgppglp gikgergytg sagekgepgp pgseglpgpp gpagprgerg
1141 pagnsgekad agfagapaft aptaspafpa kvaspappap aekasegir apsalpaspa
1201 ppgppgiqgp agldgldgkd gkpglrgdpg pagppglmgp pgfkgktghp glpgpkgdcg
1261 kpgppgstgr pgaegepgam gpqgrpgppg hvgppgppgq pgpagisavg lkgdrgatge
1321 rglaglpgqp gppghpgppg epgtdgaagk egppgkqgfy gppgpkgdpg aagqkgqage
1381 kgragmpggp gksgsmgpvg ppgpagergh pgapgpsgsp glpgvpgsmg dmvnydeikr
1441 firqeiikmf dermayytsr mqfpmemaaa pgrpgppgkd qapgrpgapg spqlpgqigr
1501 egrqqlpgvr glpgtkgekg digigiagen glpgppgpqg ppgygkmgat gpmgqqgipg
1561 ipgppgpmgq pgkaghcnps dcfgampmeq qyppmktmkg pfg
```

<u>Disclaimer | Write to the Help Desk</u> <u>NCBI | NLM | NIH</u>

Oct 4 2005 13:52:42

11



PubMed

2. Not in banded collagen fibrils in dermis, but is component of specialized

fibrillin-1-containing microfibrils. In cartilage matrix not in aggregates with fibrillin-1. Resides in thin, weakly banded collagen fibrils also containing collagens II and XI.

General gene information

3 1

Markers

STS-W96115(e-PCR) (Links: <u>UniSTS: 25967</u>) Alternate names: RH76723; sts-W96115 SHGC-35321(e-PCR) (Links: <u>UniSTS: 45868</u>) Alternate names: RH38648; RH50395; SGC35321

G15937(e-PCR) (Links: UniSTS: 72120)

Alternate names: CHLC.UTR 03582 S57132; CHLC.UTR 03582 S57132.P65059

RH69199(e-PCR) (Links: UniSTS: 73013)

Alternate name: M92642

STS-M92642(e-PCR) (Links: <u>UniSTS: 73133</u>) Alternate names: RH76257; sts-M92642

GeneOntology

Provided by GOA

Function Evidence
structural molecule activity IEA

Process
cell adhesion IEA
phosphate transport IEA
pregnancy TAS PubMed

Component

collagen type XVI TAS PubMed

cytoplasm IEA extracellular matrix (sensu Metazoa) IEA

Homology:

Mouse, Rat

Map Viewer

General protein information

?

Names: alpha 1 type XVI collagen

alpha 1 type XVI collagen; collagen XVI, alpha-1 polypeptide

NCBI Reference Sequences (RefSeq)



mRNA Sequence NM 001856

Source Sequence M92642,R54778

Product NP 001847 alpha 1 type XVI collagen precursor

Conserved Domains (1) summary

smart00210: TSPN; Thrombospondin N-terminal -like domains

Location: 50 - 231 Blast Score: 419

Related Sequences



Nucleotide		Protein
mRNA	AB209571	BAD92808
mRNA	AF370368	AAQ15204
mRNA	M92642	AAA58427
mRNA	R54778	None
mRNA	S57132	AAB25797

Gene Page 3 of 3

mRNA X14963 mRNA X15038

X14963 CAA33085 X15038 CAA33142 None Q07092

Q16593 Q59F89 Q71RG9

Additional Links

UniGene <u>Hs.368921</u> MIM <u>120326</u> HPRD <u>00381</u>

Display Full Report Show 5 Send to

Restrictions on Use | Write to the Help Desk NCBI | NLM | NIH

Nov 3 2005 04:38:48

3 1